U.S. Court Overturns Ranbaxy's Bid to Block Rival Generics

Nov 20, 2014

Reuters

A U.S. court has denied a request by India's Ranbaxy Laboratories to stop competitors from launching generic copies of AstraZeneca's heartburn pill Nexium and Roche's antiviral, Valcyte.

Last week, Ranbaxy sued the U.S. FDA for revoking approvals granted to launch generic copies of AstraZeneca's Nexium and Roche's Valcyte.

Ranbaxy had also sought to prevent Endo International and Dr Reddy's from making their own generic versions of Valcyte after the FDA gave the two companies final approvals.

According to the court filing, Ranbaxy's request was denied by U.S. District Judge Beryl Howell in Minneapolis.

Read the Reuters press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

  • <p>precious more effective</p>

    Reply

RSS feed for comments on this page | RSS feed for all comments